SecBot SecBot
SECBOTREPLAY Home › Report › OCGN

OCGN · Ocugen announced completion of patient enrollment in the Phase 3…

Ocugen · PRESS-RELEASE filed Mar 2, 2026 at 07:02 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 2, 2026 at 07:02 ET

Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therapy OCU400 in retinitis pigmentosa (RP), with topline data expected in Q1 2027. The company also reported positive 3-year Phase 1/2 data showing durable vision improvement and a favorable safety profile, reinforcing the potential for a gene-agnostic treatment. BLA filing is on track for Q3 2026.

  • Enrollment completed in OCU400 Phase 3 liMeliGhT trial with 140 patients randomized 2:1 across RHO and gene-agnostic RP mutations.
  • Topline Phase 3 data expected in Q1 2027, supporting potential approval in 2027.
  • Positive 3-year Phase 1/2 data show 88% of treated eyes maintained or improved vision, with ~2-line LLVA gain sustained across mutations.
  • No new treatment-related serious adverse events reported; safety profile remains favorable.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access